• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NLS Pharmaceutics Ltd. - Warrant (NQ:NLSPW)

0.0169 UNCHANGED
Streaming Delayed Price Updated: 3:53 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0169
Bid (Size) 0.0166 (15)
Ask (Size) 0.0252 (1,242)
Prev. Close 0.0169
Today's Range 0.0169 - 0.0169
52wk Range 0.0009 - 0.0698
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
March 31, 2025
Via ACCESS Newswire
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 11, 2024
Via ACCESSWIRE

Performance

YTD
+40.8%
+40.8%
1 Month
-15.5%
-15.5%
3 Month
+312.2%
+312.2%
6 Month
+44.4%
+44.4%
1 Year
-41.3%
-41.3%

More News

Read More
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
December 03, 2024
Via ACCESSWIRE
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
November 18, 2024
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
October 28, 2024
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
October 15, 2024
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
September 25, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Registered Direct Offering
June 28, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
June 27, 2024
Via ACCESSWIRE
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
June 25, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
June 11, 2024
Via ACCESSWIRE
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
May 28, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
May 24, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
April 19, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
March 22, 2024
Via ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
March 20, 2024
Via ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
March 20, 2024
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
March 14, 2024
Via ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
March 11, 2024
Via ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
February 23, 2024
Via ACCESSWIRE
Notice of Deficiency with Nasdaq Continued Listing Requirements
January 12, 2024
Via ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 29, 2023
Via ACCESSWIRE
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
December 01, 2023
Via ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
November 28, 2023
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
November 27, 2023
Via ACCESSWIRE

Frequently Asked Questions

Is NLS Pharmaceutics Ltd. - Warrant publicly traded?
Yes, NLS Pharmaceutics Ltd. - Warrant is publicly traded.
What exchange does NLS Pharmaceutics Ltd. - Warrant trade on?
NLS Pharmaceutics Ltd. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for NLS Pharmaceutics Ltd. - Warrant?
The ticker symbol for NLS Pharmaceutics Ltd. - Warrant is NLSPW on the Nasdaq Stock Market
What is the current price of NLS Pharmaceutics Ltd. - Warrant?
The current price of NLS Pharmaceutics Ltd. - Warrant is 0.0169
When was NLS Pharmaceutics Ltd. - Warrant last traded?
The last trade of NLS Pharmaceutics Ltd. - Warrant was at 07/29/25 03:53 PM ET
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap